Retinoids in neuroblastoma therapy: Distinct biological properties of 9- cis- and all-trans-retinoic acid

European Journal of Cancer

Volumn 33, Issue 12, 1997, Pages 2075-2080

  Lovat, P E ^a   Irving, H ^a   Annicchiarico Petruzzelli, M ^b   Bernassola, F ^b   Malcolm, A J ^a   Pearson, A D J ^a   Melino, G ^b   Redfern, C P F ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

9 cis retinoic acid; Apoptosis; Differentiation; Neuroblastoma; RAR; Receptors; Retinoids

Indexed keywords

ALITRETINOIN; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID;

APOPTOSIS; CELL DIFFERENTIATION; CHILDHOOD CANCER; CONFERENCE PAPER; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NEUROBLASTOMA; PRIORITY JOURNAL; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOATES; CELL DIFFERENTIATION; CELL DIVISION; CHROMANS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEUROBLASTOMA; RECEPTORS, RETINOIC ACID; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0031417682     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00242-6     Document Type: Conference Paper

References (45)

1. Waldmann T., Lengauer C., Kinzler K. W., Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature. 381:1996;713-716.
2. Sidell N. Retinoic acid-induced growth-inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst. 68:1982;589-596.
3. Finklestein JZ, Krailo MD, Lenarsky C, et al. 13-cis-retinoic Acid (NSC-122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy - report from the childrens cancer study group. Med Pediatr Oncol 1992, 20, 307-311.
4. Smith MA, Adamson PC, Balis FM, et al. Phase I and pharmacokinetic evaluation of all-trans retinoic acid in pediatric patients with cancer. J Clin Oncol 1992, 10, 1666-1673.
5. Villablanca JG, Khan AA, Avramis VI, et al. Phase-I trial of 13-cis-retinoic acid in children with neuroblastoma following bone-marrow transplantation. J Clin Oncol 1995, 13, 894-901.
6. Stunnenberg H. G. Mechanisms of transactivation by retinoic acid receptors. Bioessays. 15:1993;309-315.
7. Allegretto EA, McClurg MR, Lazarchik SB, et al. Transactivation properties of retinoic acid and retinoid-X receptors in mammalian-cells and yeast - correlation with hormone-binding and effects of metabolism. J Biol Chem 1993, 268, 26625-26633.
8. Zhang XK, Lehmann J, Hoffmann B, et al. Homodimer formation of retinoid X-receptor induced by 9-cis-retinoic acid. Nature 1992, 358, 587-591.
9. Willy P. J., Umesono K., Ong E. S., et al. Lxr, a nuclear receptor that defines a distinct retinoid response pathway. Genes Devel. 9:1995;1033-1045.
10. Perlmann T., Jansson L. A novel pathway for vitamin-a signaling mediated by RXR heterodimerization with NGFi-B and Nurr1. Genes Devel. 9:1995;769-782.
11. Shalinsky DR, Bischoff ED, Gregory ML, et al. Retinoid-induced suppression of squamous-cell differentiation in human oral squamous-cell carcinoma xenografts (line-1483) in athymic nude mice. Cancer Res 1995, 55, 3183-3191.
12. Kizaki M, Nakajima H, Mori S, et al. Novel retinoic acid, 9-cis-retinoic acid, in combination with all-trans-retinoic acid is an effective inducer of differentional of retinoic acid-resistant H1-60 cells. Blood 1994, 83, 3289-3297.
13. Anzano MA, Byers SW, Smith JM, et al. Prevention of breast-cancer in the rat with 9-cis-retinoic acid as a single-agent and in combination with tamoxifen. Cancer Res 1994, 54, 4614-4617.
14. Anzano MA, Peer CW, Smith JM, et al. Chemoprevention of mammary carcinogenesis in the rate - combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 1996, 88, 123-125.
15. Gottardis M. M., Lamph W. W., Shalinsky D. R., Wellstein A., Heyman R. A. The efficacy of 9-cis-retinoic acid in experimental models of cancer. Breast Cancer Res Treat. 38:1996;85-96.
16. Rubin M, Fenig E, Rosenauer A, Menendezbotet C, et al. 9-cis-retinoic acid inhibits growth of breast-cancer cells and down-regulates estrogen-receptor RNA and protein. Cancer Res 1994, 54, 6549-6556.
17. Lovat P. E., Lowis S. P., Pearson A. D. J., Malcolm A. J., Redfern C. P. F. Concentration-dependent effects of 9-cis-retinoic acid on neuroblastoma-differentiation and proliferation in vitro. Neurosci Lett. 182:1994;29-32.
18. Han G. Y., Chang B. S., Connor M. J., Sidell N. Enhanced potency of 9-cis versus all-trans-retinoic acid to induce the differentiation of human neuroblastoma cells. Differentiation. 59:1995;61-69.
19. Lovat P. E., Pearson A. D. J., Malcolm A., Redfern C. P. F. Retinoic acid receptor expression during the in vitro differentiation of human neuroblastoma. Neurosci Lett. 162:1993;109-113.
20. Piacentini M., Fesus L., Melino G. Multiple cell-cycle access to the apoptotic death program in human neuroblastoma cells. FEBS Lett. 320:1993;150-154.
21. Apfel C, Bauer F, Crettaz M, et al. A retinoic acid receptor-alpha antagonist selectivity counteracts retinoic acid effects. Proc Natl Acad Sci USA 1992, 89, 7129-7133.
22. Wilkinson M. RNA isolation - a mini-prep method. Nucleic Acids Res. 16:1988;10933.
23. Redfern C. P. F., Lovat P. E., Malcolm A. J., Pearson A. D. J. Differential effects of 9-cis and all-trans-retinoic acid on the induction of retinoic acid receptor-beta and cellular retinoic acid-binding protein-Ii in human neuroblastoma cells. Biochem J. 304:1994;147-154.
24. Redfern C. P. F., Lovat P. E., Malcolm A. J., Pearson A. D. J. Gene expression and neuroblastoma cell differentiation in response to retinoic acid - differential effects of 9-cis and all-trans-retinoic acid. Eur J Cancer. 31A:1995;486-494.
25. Wyllie AH, Duvall E. Cell injury and death. In McGee JOD, Isaacson PG, Wright NA, eds. Oxford Textbook of Pathology 1. Oxford, Oxford University Press, 1992, 141-193.
26. Korsmeyer S. J. Bcl-2 initiates a new category of oncogenes - regulators of cell death. Blood. 80:1992;879-886.
27. El Badry O. M., Romanus J. A., Helman L. J., et al. Autonomous growth of a human neuro-blastoma cell-line is mediated by insulin-like growth factor-Ii. J Clin Invest. 84:1989;829-839.
28. Matthews C. C., Feldman E. L. Insulin-like growth-factor-I rescues SH-SY-5Y human neuroblastoma cells from hyperosmotic induced programmed cell death. J Cell Physiol. 166:1996;323-331.
29. Melino G., Stephanou A., Annicchiaricopetruzzelli M., et al. Modulation of IGF-2 expression during growth and differentiation of human neuroblastoma cells - retinoic acid may induce IGF-2. Neurosci Lett. 151:1993;187-191.
30. Ueno T., Suita S., Zaizen Y. Retinoic acid induces insulin-like growth factor-Ii expression in a neuroblastoma cell line. Cancer Lett. 71:1993;177-182.
31. Babajko S., Binoux M. Modulation by retinoic acid of insulin-like growth factor (IGF) and IGF binding protein expression in human SK-N-SH neuroblastoma cells. Eur J Endocrinol. 134:1996;474-480.
32. Bernardini S, Cianfarani S, Spagnoli A, et al. Expression and down-regulation by retinoic acid of IGF binding protein-2 and protein-4 in medium from human neuroblastoma cells. J Neuroendocrinol 1994, 6, 409-413.
33. Hockenbery D., Nunez G., Milliman C., Schreiber R. D., Korsmeyer S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348:1990;334-336.
34. Rodriguez-Teber A., Rohrer H. Retinoic acid induces NGF-dependent survival response and high-affinity NGF receptors in immature chick sympathetic neurons. Development. 112:1991;813-820.
35. Hanada M, Krajewski S, Tanaka S, et al. Regulation of Bcl-2 oncoprotein levels with differentiation of human neuroblastoma cells. Cancer Res 1993, 53, 4978-4986.
36. Lasorella A., Iavarone A., Israel M. A. Differentiation of neuroblastoma enhances Bcl-2 expression and induces alterations of apoptosis and drug resistance. Cancer Res. 55:1995;4711-4716.
37. Zhang K. Z., Westberg J. A., Holtta E., Andersson L. C. Bcl2 regulates neural differentiation. Proc Natl Acad Sci USA. 93:1996;4504-4508.
38. Piacentini M., Annicchiarico-Petruzzelli M., Oliverio S., et al. Phenotype-specific tissue transglutaminase regulation in human neuroblastoma cells in response to retinoic acid - correlation with cell death by apoptosis. Int J Cancer. 52:1992;271-278.
39. Kruyt FAE, Vandenbrink CE, Defize LHK, et al. Transcriptional regulation of retinoic acid receptor-beta in retinoic acid-sensitive and acid-resistant P19-embryocarcinoma cells. Mech Devel 1991, 33, 171-178.
40. Kruyt FAE, Vanderveer LJ, Mader S, et al. Retinoic acid resistance of the variant embryonal carcinoma cell line Rac65 is caused by expression of a truncated RAR-alpha. Differentiation 1992, 49, 27-37.
41. Beckwith J., Martin R. Observations of the histopathology of neuroblastomas. J Paediatr Surg. 3:1968;106-110.
42. Iwata M., Koshinaga T., Okabe I., Kurosu Y., Esumi M. Biological characteristics of neuroblastoma with spontaneous tumor reduction - a case report. J Pediatr Surg. 30:1995;722-723.
43. Kurie JM, Lee JS, Griffin T, et al. Phase-I trial of 9-cis-retinoic acid in adults with solid tumors. Clin Cancer Res 1996, 2, 287-293.
44. Miller VA, Rigas JR, Benedetti FM, et al. Initial clinical trial of the retinoid receptor pan agonist 9-cis-retinoic acid. Clin Cancer Res 1996, 2, 471-475.
45. Lovat P. E., Irving H., Malcolm A. J., Pearson A. D. J., Redfern C. P. F. 9-cis-Retinoic acid - a better retinoid for the modulation of differentiation, proliferation and gene expression in human neuroblastoma. J Neuro-Oncol. 31:1996;85-91.